United Therapeutics Outlines 14 Planned Launches Across Pulmonary Fibrosis, Hypertension and Xenotransplantation
核心洞察
United Therapeutics detailed a pipeline of 14 prospective product launches spanning pulmonary fibrosis, pulmonary hypertension (搜索) and genetically modified pig organ programs at the Bernstein Healthcare Leaders and Disruptors Conference.
The FDA accepted the company's new drug application for nebulized Tyvaso in idiopathic pulmonary fibrosis (搜索), with a PDUFA action date expected early next year after the TETON-1 and TETON-2 trials showed forced vital capacity improvement.
Ralinepag, a once-daily oral pulmonary hypertension (搜索) therapy, has been submitted to the FDA with a PDUFA date of June 24 next year, and a triple-combination version is in development.
United Therapeutics outlined a pipeline of 14 prospective product launches across pulmonary fibrosis, pulmonary hypertension (搜索) and organ manufacturing at the Bernstein Healthcare Leaders and Disruptors Conference, where founder, chairperson and chief executive officer Martine Rothblatt described the company as positioned for an "exponential growth trajectory."
Nebulized Tyvaso Moves Toward an IPF Decision
The FDA has accepted United Therapeutics' new drug application for nebulized Tyvaso in idiopathic pulmonary fibrosis (搜索) (IPF), with a PDUFA action date expected early next year. The company also plans to pursue use of Tyvaso DPI, its approved dry-powder inhalation product, in IPF and progressive pulmonary fibrosis (搜索) (PPF).
Rothblatt said the company used secondary endpoints from its prior INCREASE study in pulmonary hypertension (搜索) with interstitial lung disease (搜索) (PH-ILD) to support its request to move into a Phase III IPF study. The FDA required two adequate and well-controlled Phase III trials in IPF, she said. United Therapeutics subsequently completed the TETON-1 and TETON-2 studies, which Rothblatt said showed an improvement in forced vital capacity. She said the results supported the company's expectation that Tyvaso could provide a meaningful clinical benefit for pulmonary fibrosis patients.
United Therapeutics has doubled its sales force in preparation for a potential IPF launch and plans to launch in Europe as well, according to Rothblatt. For PPF, she said the FDA allowed the company to conduct a single study. That trial is fully enrolled, with results expected to be unblinded next year.
Inhaled and Oral Candidates Across Fibrosis and Hypertension
The company is developing CoughLess Trezmi (搜索), a soft-mist inhaled therapy, for ILD, IPF and PPF. United Therapeutics expects to submit an NDA for that product before year-end and anticipates a launch next year, Rothblatt said.
Another pipeline candidate, Once Daily Ralpi (搜索), is being developed for IPF, PPF and ILD. Rothblatt said the molecule has once-daily dosing potential and, in the company's view, has stronger anti-fibrotic activity than treprostinil.
United Therapeutics has submitted ralinepag, a once-daily oral therapy for pulmonary hypertension (搜索), to the FDA. Rothblatt said the agency assigned a PDUFA date of June 24 next year. She described ralinepag as the only drug tested in pulmonary hypertension that demonstrated clinical improvement in patients, in addition to slowing disease progression. The company is also developing a triple-combination version of ralinepag that would include a PDE5 inhibitor (搜索) and an endothelin receptor (搜索) antagonist, or ERA, in a single pill, a program Rothblatt said is intended to reduce patients' pill burden.
Other development programs include TRESMI (搜索) for COPD-associated pulmonary hypertension (搜索), an indication Rothblatt said affects about 600,000 U.S. patients and currently has no approved therapies. The company is also developing ILO Tra (搜索), a rescue inhaler for pulmonary hypertension that combines two prostacyclin-type molecules.
Xenokidney Registration Trial Advances
Rothblatt detailed United Therapeutics' xenotransplantation programs, which use genetically modified pig organs for human transplantation. The company is conducting a registration trial of its xenokidney program, with four patients already transplanted and two additional procedures planned this year, she said.
After the sixth patient reaches three months following transplantation, United Therapeutics expects to present data to the FDA to seek authorization to continue the trial. Rothblatt said the company expects the trial to enroll 30 patients in total by 2028 and aims for potential commercial availability no later than 2030.
The company has built three commercial xenograft production facilities in Virginia, Rochester, Minnesota, and Houston. Chief financial officer James Edgemond said United Therapeutics adjusted its manufacturing plans over time to reduce upfront capital requirements and better align future facility investments with commercial demand.
United Therapeutics is also pursuing clinical programs involving xenotransplanted hearts and its UThymoKidney and UHeart concepts. Rothblatt said those programs incorporate thymus tissue intended to train a recipient's immune system to recognize the transplanted pig organ, potentially reducing or eliminating the need for chronic immunosuppression.
In Silico Lung Modeling
Rothblatt highlighted the company's Computational Laboratory for In Silico Molecular Biology, or CLIMB, which she said was developed to create a detailed digital model of the lung for evaluating potential treatments in pulmonary hypertension (搜索) and pulmonary fibrosis. She said the company has used the model in assessing internal drug candidates and is receiving interest from pharmaceutical companies seeking to test their molecules through the platform.
United Therapeutics' marketed PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.